Alioune Badara Diallo

Dr. Alioune Badara Diallo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMoussa Seck
Moussa Seck
ASAlioune Badara Senghor
Alioune Badara Senghor
MLMossane Loum
Mossane Loum
STSokhna Aissatou Touré
Sokhna Aissatou Touré
BFBlaise Félix Faye
Blaise Félix Faye
SDSaliou Diop
Saliou Diop
Context and Objectives: Blood transfusions (BT) remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. We aim to assess infectious markers, red cell alloimmunization and iron overload secondary to BT in SCD patients. Materials and Methods: This is a case-control study included 253 SCD (153 SCD-transfused and 100 SCD non-transfused). We evaluated the transfusion practice (modalities, indications), post-transfusion complications (infections, alloimmunization, iron overload) and risk factors of these complications (socio-demographic, clinical, biological). Results: Median age was 28.5 years (5 - 59). Sex ratio was 0.86. Homozygous SCD was more common (95.3%). Simple BT was performed in 92.8% and transfusion exchange in 18.9%. Transfusion indications were dominated by acute anemia (57.06%) and vaso-occlusive crisis (VOCs) (14%). Red blood cell concentrates (RBC) were administered to 93.46%. Median number of RBC received per patient was 10 (2 - 48). The prevalence of VHC in SCD-transfused was 1.33% and 2% for VHB. Anti-HIV antibodies were not found. Red cell alloimmunization frequency was 16%. The most common alloantibodies were anti-rhesus (34.19%) and anti-Kell (23.67%). Iron overload was detected in 7.84%. The number of RBC transfused was the only risk factor for alloimmunization (p = 0.03) and iron overload (p = 0.023). BT frequency was not related to infectious transmission. Conclusion: Despite advances in blood safety, BT therapy is still a risk for SCD polytransfused patients. Although infectious transmission has rare, the risk of alloimmunization and iron overload is high in these patients.

13 February 2020 in International Journal of Biological and Chemical Sciences
Verified
Journal Article
Open access
PDF file
TYTINE Yoro
TINE Yoro
MDMoussa Diop
Moussa Diop
INIdrissa Ndoye
Idrissa Ndoye
ADAlioune Badara Diallo
Alioune Badara Diallo
AWAlassane Wele
Alassane Wele
Cette étude avait pour objectif de faire le point sur la composition chimique et les activités biologiques de G. senegalensis, une plante médicinale largement utilisée en Afrique par les guérisseurs traditionnels pour le traitement de divers troubles. La plupart de ces études chimiques ont porté sur le criblage phytochimique des extraits de feuilles, de racines, de tiges et de galles. Elles ont montré la présence d'hydrates de carbone, de stéroïdes, de saponines, de flavonoïdes, d’alcaloïdes, de tanins, de saponines, de glycosides cardiaques, de coumarines, d’anthraquinones, d’acide ascorbique, d’hétérosides cardiotoniques, de cyanogènes et de terpénoïdes. Les potentialités thérapeutiques des extraits de G.  senegalensis rapportées dans plusieurs travaux scientifiques ont porté sur les activités antibactériennes, antitussives, antidiarrhéiques, cytotoxiques, anti-inflammatoires antipaludiques, antitrypanosomiques, antihelminthiques, antivirales et antioxydantes. Des études de toxicité sur ces extraits ont été aussi réalisées. Ainsi, des études de caractérisation chimique (variabilité chimique), de formulation galénique et aussi de toxicité clinique sur G. senegalensis doivent être menées afin de mettre en place des produits de phytothérapie moderne. Mots clés: Phytochimie, pharmacologie, feuilles, Guiera senegalensis. English Title: Review on the chemical composition and biological activities of Guiera senegalensis J.F. Gmel. (Combretaceae) The aim of this study was to review the chemical composition and biological activities of G. senegalensis, a medicinal plant widely used in Africa by traditional healers for the treatment of various disorders. Most of these chemical studies have focused on the phytochemical screening of leaf, root, stem and gall extracts. They showed the presence of carbohydrate, steroids, saponins, flavonoids, alkaloids, tannins, saponins, cardiac glycosides, coumarins, anthraquinones, ascorbic acid, cardiotonic glycosides, cyanogens and terpenoids. The therapeutic potentialities of extracts of G. senegalensis reported in several scientific studies have focused on antibacterial, antitussive, antidiarrheal, cytotoxic, anti-inflammatory, antimicrobial, antitrypanosomal, anthelmintic, antiviral and antioxidant activities. Toxicity studies on these extracts have also been carried out. Thus, chemical characterization studies (chemical variability), galenic formulation and clinical toxicity studies on G. senegalensis must be carried out in order to implement modern phytotherapy products. Keywords: Phytochemistry, pharmacology, leaves, Guiera senegalensis.

1 January 2024 in Anemia
Verified
Journal Article
Open access
ADAlioune Badara Diallo
Alioune Badara Diallo
MSMoussa Seck
Moussa Seck
STSokhna Aissatou Touré
Sokhna Aissatou Touré
MKMohamed Keita
Mohamed Keita
EBElimane Seydi Bousso
Elimane Seydi Bousso
SDSaliou Diop
Saliou Diop
Introduction: Sickle cell emergencies are the most common cause of hospitalization for patients with sickle cell disease (SCD). Hospital readmissions represent a considerable financial burden for healthcare systems and increase patient morbidity and mortality. The aim of this study was to assess the prevalence and predictive factors of sickle cell emergencies readmission.Materials and Methods: We conducted a prospective, cross‐sectional, descriptive, and analytical study over a 4‐month period, including all adult patients admitted for an emergency related to SCD: vaso‐occlusive crisis (VOC), acute chest syndrome (ACS), severe anemia, infections, priapism, and stroke. Readmission was considered when the patient returned to the emergency within a period of <30 days, either due to recurrence, persistence of the same complication, or the occurrence of another acute complication related to SCD.Results: We recorded 151 sickle cell emergencies for 112 patients, representing 0.33 emergencies/month/patient. Fifty‐eight cases of readmission were recorded, resulting in a readmission rate of 38.41%. Among these patients, 53 (91.37%) had two admissions, and 5 (8.62%) had three admissions. The median age of the patients was 28.41 years (16–70 years), and the sex ratio was 0.57. The SS sickle cell phenotype was predominant in 97 patients (86.61%). The reasons for readmission were VOC (82.75%), ACS (13.72%), and severe anemia (3.44%). The main factors that predicted readmission were the existence of professional activity, a low fetal hemoglobin (HbF) level, the existence of neutrophilia, lymphocytosis, and/or thrombocytosis (p values of 0.0084, 0.043, and 0.020 respectively).Conclusion: The 30‐day readmission rate after a sickle cell emergency is high in our study. The main factors that predicted readmission were the existence of professional activity, a relatively low level of fetal Hb, the existence of neutrophilia, lymphocytosis, and/or thrombocytosis.

18 October 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ADAlioune Badara Diallo
Alioune Badara Diallo
MSMoussa Seck
Moussa Seck
MKMohamed Keita
Mohamed Keita
STSokhna Aissatou Touré
Sokhna Aissatou Touré
EBElimane Seydi Bousso
Elimane Seydi Bousso
SDSali̇oU Diop
Sali̇oU Diop
Background/aim: The evolution of sickle cell disease (SCD) is marked by the occurrence of painful episodes linked to the obstruction of micro-vessels by sickle cells, known as vaso-occlusive crises (VOC). The aim of our work was to report the practical aspects of the management of acute pain in adults with SCD. Recommendations based on these practices are also provided.Materials and methods: We conducted a prospective, cross-sectional, descriptive and analytical study over a 4-month period of all sickle cell patients admitted to emergency departments for VOC. The parameters studied were sociodemographic, clinico-biological, therapeutic and evolutionary.Results: 118 cases of VOC were identified, representing a prevalence of 78.14% of sickle cell emergencies. The mean age of the patients was 28.41 years. The SS sickle cell phenotype accounted for 86.61% of cases. Osteoarticular pain was the reason for admission in 88.39% of cases; it was located in the lower limbs in 39.08% of cases and in the spine in 27.1% of cases. Pain intensity was moderate in 6.25% of cases, intense in 31.25% and unbearable in 55.55%. Multimodal analgesia was the most commonly used treatment method, combining levels 1 and 2 (74.31%) and levels 1 and 3 (8.25%). The mean dose of morphine administered was 17.14 mg when morphine alone was prescribed for titration, 13.57 mg when paracetamol and morphine were combined, and 15.83 mg when nefopam and morphine were combined. Clinical outcome was favourable in 68.87% of cases.Conclusion: We noticed a wide variability in the modalities of analgesic treatment of sickle cell VOC. These variations reflect different views on the appropriateness of opioids. This study highlights the efficacy of multimodal analgesia in the management of acute pain in patients with SCD, particularly with regard to morphine sparing. Context-specific recommendations will be needed to harmonize practices.

1 January 2026 in Advances in Hematology
Verified
Journal Article
Open access
ADAlioune Badara Diallo
Alioune Badara Diallo
BFBlaise Félix Faye
Blaise Félix Faye
STSokhna Aissatou Touré
Sokhna Aissatou Touré
EBElimane Seydi Bousso
Elimane Seydi Bousso
MKMohamed Keita
Mohamed Keita
SDSaliou Diop
Saliou Diop
Spontaneous tumor lysis syndrome (sTLS) is a life‐threatening oncometabolic emergency that remains poorly documented in low‐resource settings. This retrospective cohort study aimed to assess the prevalence, risk factors, and prognostic implications of sTLS in adults with aggressive hematologic malignancies in Dakar, Senegal. Twenty‐six newly diagnosed patients (18 with aggressive non‐Hodgkin lymphomas and 8 with acute leukemias) were included between April 2020 and April 2021. sTLS was defined according to the Cairo–Bishop criteria. Clinical, biological, and survival data were analyzed using univariate tests and Kaplan–Meier estimates. The prevalence of sTLS was 30.8% (8/26). Acute kidney injury was the only factor significantly associated with sTLS ( p = 0.005), while hyperleukocytosis and bulky tumor burden were not correlated. All patients received hyperhydration, and patients at high risk received allopurinol, resulting in normalization of metabolic disturbances within 1 week. Early mortality (≤ 3 months) occurred in 15.4% of patients, and overall mortality reached 38.5%, mainly due to advanced disease. Survival did not differ significantly between patients with and without sTLS (log‐rank = 0.7). In conclusion, sTLS is frequent in Senegalese patients with aggressive hematologic malignancies. Early detection and basic supportive care remain effective for preventing fatal complications in the absence of rasburicase.

3 July 2024 in Hemoglobin
Verified
Journal Article
Closed access
MKMohamed Keita
Mohamed Keita
MSMoussa Seck
Moussa Seck
ADAlioune Badara Diallo
Alioune Badara Diallo
STSokhna Aissatou Touré
Sokhna Aissatou Touré
EBElimane Seydi Bousso
Elimane Seydi Bousso
SDSaliou Diop
Saliou Diop
SUMMARYCOVID-19 infection has emerged as a comorbidity that can significantly increase morbidity and mortality in sickle cell patients with ACS (acute thoracic/chest syndrome). The aim of our study was to assess COVID-19-related morbidity and mortality in sickle cell patients with ACS. This was a retrospective, descriptive study of patient records followed over a 36-month period from January 2020 to December 2022. The study was conducted at the national blood transfusion center in Dakar. The sex ratio (M/F) was 0.82. The median age was 26 (17-39) years. The most represented age group was between 21 and 30 years. Factors associated with death were: at baseline, SS genotype, presence of comorbidities (asthma, chronic obstructive pulmonary disease, viral hepatitis B, ischemic heart disease), osteonecrosis of the femoral head, and use of NSAIDs (non-steroidal anti-inflammatory drugs) at diagnosis of COVID-19; at the diagnosis of ACS associated with COVID-19, respiratory distress, hypoxia (Sa02 < 92%), creatininemia >18.5 mg/l, CRP >192 mg/l, lymphopenia; the therapeutic modalities associated with death were: transfusion of RBCs (packed red blood cells) and curative anticoagulation. This study shows that patients with comorbidities and/or chronic complications of sickle cell disease can develop severe forms of ACS associated with COVID 19, leading to death. Other factors linked to death, notably diagnostic and therapeutic, were also identified in the course of this study.